

University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln

Faculty Publications in Food Science and
Technology

Food Science and Technology Department

2020

Stool microbiome, pH and short/branched chain fatty acids in infants receiving extensively hydrolyzed formula, amino acid formula, or human milk through two months of age

Car Reen Kok

Bradford Brabec

Maciej Chichlowski

Cheryl L. Harris

Nancy Moore

See next page for additional authors

Follow this and additional works at: <https://digitalcommons.unl.edu/foodsciefacpub>



Part of the [Food Science Commons](#)

This Article is brought to you for free and open access by the Food Science and Technology Department at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications in Food Science and Technology by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Car Reen Kok, Bradford Brabec, Maciej Chichlowski, Cheryl L. Harris, Nancy Moore, Jennifer L. Wampler, Jon Vanderhoof, Devin Rose, and Robert W. Hutkins

RESEARCH ARTICLE

Open Access



Stool microbiome, pH and short/branched chain fatty acids in infants receiving extensively hydrolyzed formula, amino acid formula, or human milk through two months of age

Car Reen Kok¹, Bradford Brabec², Maciej Chichlowski³, Cheryl L. Harris⁴, Nancy Moore⁴, Jennifer L. Wampler⁴, Jon Vanderhoof⁵, Devin Rose⁶ and Robert Hutkins^{7*}

Abstract

Background: Early infant feeding with intact or extensively hydrolyzed (EH) proteins or free amino acids (AA) may differentially affect intestinal microbiota composition and immune reactivity. This multicenter, double-blind, controlled, parallel-group, pilot study compared stool microbiota from Baseline (1–7 days of age) up to 60 days of age in healthy term infants who received mother's own milk (assigned to human milk [HM] reference group) ($n = 25$) or were randomized to receive one of two infant formulas: AA-based (AAF; $n = 25$) or EH cow's milk protein (EHF; $n = 28$). Stool samples were collected (Baseline, Day 30, Day 60) and 16S rRNA genes were sequenced. Alpha (Shannon, Simpson, Chao1) and beta diversity (Bray Curtis) were analyzed. Relative taxonomic enrichment and fold changes were analyzed (Wilcoxon, DESeq2). Short/branched chain fatty acids (S/BCFA) were quantified by gas chromatography. Mean S/BCFA and pH were analyzed (repeated measures ANOVA).

Results: At baseline, alpha diversity measures were similar among all groups; however, both study formula groups were significantly higher versus the HM group by Day 60. Significant group differences in beta diversity at Day 60 were also detected, and study formula groups were compositionally more similar compared to HM. The relative abundance of *Bifidobacterium* increased over time and was significantly enriched at Day 60 in the HM group. In contrast, a significant increase in members of Firmicutes for study formula groups were detected at Day 60 along with butyrate-producing species in the EHF group. Stool pH was significantly higher in the AAF group at Days 30 and 60. Butyrate increased significantly from Baseline to Day 60 in the EHF group and was significantly higher in study formula groups vs HM at Day 60. Propionate was also significantly higher for EHF and AAF at Day 30 and AAF at Day 60 vs HM. Total and individual BCFA were higher for AAF and EHF groups vs HM through Day 60.

(Continued on next page)

* Correspondence: rhutkins1@unl.edu

⁷Department of Food Science and Technology, University of Nebraska, 258 Food Innovation Center, Lincoln, NE 68588-6205, USA

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

Conclusions: Distinct patterns of early neonatal microbiome, pH, and microbial metabolites were demonstrated for infants receiving mother's own milk compared to AA-based or extensively hydrolyzed protein formula. Providing different sources of dietary protein early in life may influence gut microbiota and metabolites.

Trial registration: ClinicalTrials.gov Identifier: [NCT02500563](https://clinicaltrials.gov/ct2/show/study/NCT02500563). Registered July 28, 2015.

Keywords: Infant formula, Infant microbiota, *Bifidobacterium*, Short chain fatty acids

Background

Cow's milk allergy (CMA) is one of the most common food allergies affecting infants [1, 2]. Allergen exclusion, through use of formulas based on extensively hydrolyzed (EH) proteins, has traditionally been used to manage CMA. Amino acid (AA)-based formulas have also become available and may be used in more severe cases [3]. However, recent data suggest that use of AA-based formulas may delay the acquisition of immune tolerance [4], potentially due to the complete absence of allergenic epitopes that are required to induce oral tolerance through early exposure of intact dietary proteins [5, 6]. Unlike AA-based formulas, the presence of small peptide fragments in protein hydrolysates has been related to the stimulation of immune tolerance to cow's milk protein [7]. This is particularly relevant with the advent of a new paradigm in the management of food allergy in infants that involves stimulation of the development of immune tolerance to food antigens. Whereas hydrolyzed formulas can minimize antigen contact, the mechanism of action also includes the induction of immune tolerance [8].

Oral tolerance development research has recently focused on the influence of host-microbe interactions on immune function, specifically that the presence of certain intestinal microbes could promote tolerance to dietary antigens [9–11]. For example, consumption of *Lactobacillus rhamnosus* GG (in EH formula) by infants with CMA was reported to stimulate immune tolerance [4, 12, 13]. One hypothesized mechanism of enhanced immune tolerance is enrichment of butyrate-producing bacteria, with butyrate stimulating the development of regulatory T (T_{reg}) cells. As known mediators of oral tolerance [14–17], T_{reg} cells have a demonstrated protective role, and a reduction could lead to an allergic phenotype [18, 19]. Ruotula and colleagues demonstrated that an increase in highly activated T_{reg} cells was associated with colonization of butyrate-producing bacteria and suggested a very narrow window of opportunity (birth up to 3 months of age) for the primary prevention of atopic diseases [20]. Given the potential of protein hydrolysates to induce oral tolerance, we hypothesized that EH-based formulas encourage the production of butyrate through the enrichment of butyrate-producing microbes. Therefore, the primary goals of this study were to assess the effects of EH and AA-based formulas on the intestinal microbial composition of infants

and the subsequent shift in formation of short and branched chain fatty acids. Preliminary findings were previously reported at the Nutrition 2019 - American Society of Nutrition annual conference [21, 22].

Results

Participants

A total of 78 participants were enrolled and assigned to a study group (EHF: $n = 28$; AAF: $n = 25$; HM: $n = 25$) (Fig. 1). Participants who were randomized but consumed no study formula (EHF: $n = 2$; AAF: $n = 1$) were not included in subsequent analyses. No differences in body weight, length, or head circumference were observed between groups at study enrollment (Table 1); sex, race and ethnic distribution were similar among groups (Additional File 1: Table S1). Statistically significant differences were detected at Day 30 in weight and length for the EHF vs HM group and at Day 60 in weight for the EHF and AAF vs HM groups. No differences in head circumference were detected at any study time point. No group differences in study formula intake (mean \pm SE; fl oz./day) were detected between study formula groups at Day 30 (EHF: 27.8 ± 1.4 vs AAF: 25.8 ± 1.5 ; $P = 0.355$) or Day 60 (EHF: 33.4 ± 2.0 vs AAF: 28.7 ± 2.2 ; $P = 0.128$). No statistically significant group differences were detected for study discontinuation (EHF: $n = 8$, 31%; AAF: $n = 10$, 42%; HM: $n = 8$, 32%; $P = 0.685$) or discontinuation related to study formula (EHF: $n = 4$, 15%; AAF: $n = 3$, 13%). In the total study population, two participants discontinued due to formula intolerance as determined by the study investigator (EHF: $n = 1$; AAF: $n = 1$). Parental decision was the most common reason for discontinuation unrelated to study formula (5 participants). A total of four participants experienced serious adverse events and were categorized within the following body systems: Gastrointestinal (HM, $n = 1$), Respiratory (EHF, $n = 1$; AAF, $n = 1$; HM, $n = 1$), or Urogenital (EHF, $n = 1$). Participants who completed the study (EHF: $n = 18$; AAF: $n = 14$; HM: $n = 17$) provided stool data at all study time points and were included in subsequent analyses.

Alpha and beta diversity

To compare overall changes in taxonomic profiles within and between each feeding group, alpha and beta diversity measures were calculated. Alpha diversity remained relatively stable from Baseline to Day 30 and from Baseline to Day 60 for the HM group when measured using




Table 1 Achieved weight, length, and head circumference^a

Age (Days)	Group (n)	Weight (g)	Length (cm)	Head circumference (cm)
1–7 (Baseline)	AAF (24)	3294 ± 77	50.8 ± 0.04	34.3 ± 0.2
	EHF (26)	3296 ± 74	50.4 ± 0.04	34.9 ± 0.2
	HM (25)	3243 ± 76	50.9 ± 0.04	34.9 ± 0.2
30	AAF (16)	4073 ± 112	53.8 ± 0.05	37.2 ± 0.3
	EHF (20)	3912 ± 100 ^b	52.8 ± 0.05 ^b	36.9 ± 0.2
	HM (20)	4345 ± 100	54.8 ± 0.05	37.7 ± 0.2
60	AAF (15)	4939 ± 127 ^b	57.0 ± 0.05	39.1 ± 0.3
	EHF (18)	4781 ± 118 ^b	57.1 ± 0.05	38.9 ± 0.2
	HM (19)	5295 ± 114	58.2 ± 0.05	39.5 ± 0.2

^a Mean ± standard error (SE)


^b Significantly lower than HM, *P* < 0.05, two-tailed test


Shannon and Simpson indices; whereas Chao1 richness significantly increased from Baseline to Day 60 (Fig. 2a). In contrast, alpha diversity increased over time in the AAF and EHF groups and was significantly higher for each compared to the HM group at Day 60 by all measures. Significant differences were also detected between Day 30 and Day 60 for the EHF (all measures) and AAF groups (Shannon index only). To assess community differences in beta diversity, PCoA plots were constructed using Bray-Curtis distance matrix (Fig. 2b). Overall community differences were detected (PERMANOVA, $P = 0.001$) with AAF and EHF communities displaying

higher similarities at Day 60, compared to the HM group.

Compositional change of genus level relative abundance between baseline and days 30 and 60


Differences in taxonomic relative abundance between Baseline and Day 30 and between Baseline and Day 60 were evaluated using Wilcoxon tests and visualized for each group by heat tree mapping. For all 3 groups, significant taxonomic changes began to appear by Day 30 (Fig. 3). In the AAF and EHF groups, members of Firmicutes (e.g. *Lachnospiraceae*) were already significantly





higher at Day 30 (Fig. 3a,c). In the AAF group, there was an observed increase in *Lactobacillus* and *Enterococcus* and a decrease in *Rothia* at both Days 30 and 60 (Fig. 3a,b). At Day 60, an increase was observed in *Akkermansia*, *Actinomyces*, *Eggerthella*, *Peptoniphilus*, *[Ruminococcus]*, *Blautia*, *Dorea*, *Ruminococcus* and *[Eubacterium]* together with a decrease in *Veillonella* and *Streptococcus*. In the EHF group, there was an observed increase in *Enterococcus* at both Days 30 and 60 (Fig. 3c,d). By Day 60, *Eggerthella*, *Lactobacillus*, *[Ruminococcus]* and members of *Clostridiaceae* and *Ruminococcaceae* were significantly higher while *Escherichia*, *Bacteroides* and *Streptococcus* had significantly decreased. For the HM group (Fig. 3e,f), members of Actinobacteria were significantly higher at Day 30. By Day 60, a significant increase in *Bifidobacterium* and *Lactobacillus* and a significant decrease in *Staphylococcus* were observed.

To further evaluate the differential abundance of specific Amplicon Sequence Variants (ASVs, unique DNA sequence from a marker gene) from Baseline and Day 60, the DESeq2: differential gene expression analysis based on the negative binomial distribution package in R was used to compute log₂-fold changes (log₂FC) of ASVs. Similar results were observed as before. In the AAF (Fig. 4a) and EHF (Fig. 4b) groups, a significant shift in members of Firmicutes were observed. This included an increase in *Enterococcus* and *Blautia* species and species belonging to the Clostridia IV and XIVa clusters, such as *Ruminococcus*, *Dorea*, *Eubacterium*, *Roseburia*, *Faecalibacterium*, and *Coprococcus*. A significant decrease in species of *Staphylococcus*, *Streptococcus*, *Veillonella*, in addition to other decreases in *Bacteroides* and *Rothia*, were also observed. In the HM group (Fig. 4c), overall shifts in



members of Firmicutes were less apparent. However, a significant increase in *Dialister* and *Finegoldia*, which was not observed in the formula-fed groups occurred in the HM group.

When organisms associated with butyrate production were assessed, two different *Roseburia* ASVs (\log_2FC of 1.2 and 3.9), and a *Faecalibacterium prausnitzii* ASV (\log_2FC of 3.9) increased in the EHF group. *Roseburia* and *Faecalibacterium* were both predictors in the random forest variable importance plots for the EHF group (Additional File 1: Fig. S1b). In comparison, a *Roseburia* ASV and a *Faecalibacterium prausnitzii* ASV increased in the AAF (\log_2FC of 1.6 and 1.8 respectively) group. A significant enrichment of *Akkermansia* (\log_2FC of 3.06) was observed in the AAF group (similarly observed by Wilcoxon test and random forest analysis) (Fig. 3a, 4a, Additional File 1: Fig. S1a). Changes in different bifidobacteria species occurred in each group. A *Bifidobacterium longum* ASV was enriched in the HM group (\log_2FC of 2) but decreased in the AAF (\log_2FC of -2.7) and EHF (\log_2FC of -1.6) groups. *Bifidobacterium pseudocatenulatum* corresponded to a single ASV enriched in the AAF group (\log_2FC of 1.2) and the two most enriched *Bifidobacterium* ASVs in the EHF group (\log_2FC of 2.4 and 2.7). Random forest analysis also demonstrated that *Bifidobacterium* ASVs were the main predictors reflecting whole microbiome changes between Baseline and Day 60 for the EHF and HM groups (Additional File 1: Fig. S1).


Group differences in genus level relative abundance at day 60

Relative abundance between study groups at Day 60 was also analyzed by a pairwise Wilcoxon comparison (Fig. 5).

Bifidobacterium was significantly higher and Firmicutes significantly lower for the HM group compared to AAF (Fig. 5a) and EHF (Fig. 5c) groups. Enterobacteriaceae, *Rothia* and *Clostridium* were significantly higher and *Akkermansia* and *Peptoniphilus* were significantly lower for the EHF compared to the AAF group (Fig. 5b).

pH and S/BCFA

Stool pH values (mean \pm SE) were similar among groups at Baseline with no significant changes for EHF and HM through Day 60. However, compared to EHF and HM, mean pH values in the AAF group were significantly higher at Days 30 ($P < 0.01$ for both) and 60 ($P < 0.01$ for both) (Fig. 6a). With the exception of propionate (HM significantly lower vs EHF group), no significant group differences in S/BCFA ($\mu\text{mol/g}$; mean \pm SE) were detected at Baseline. Butyrate increased significantly from Baseline to Day 60 in the EHF group ($P = 0.026$) and was significantly higher vs HM at Days 30 and 60 ($P < 0.01$) (Fig. 6c). Butyrate was also significantly higher for AAF vs HM at Day 60 ($P = 0.038$). In the AAF group, propionate levels significantly increased from Baseline to Day 30 ($P < 0.01$) and from Baseline to Day 60 ($P = 0.026$) and was also significantly higher compared to the HM group at Days 30 ($P < 0.01$) and 60 ($P = 0.01$) (Fig. 6d). Total SCFA was similar for all groups through Day 30 but was significantly higher in the AAF versus HM group at Day 60 ($P = 0.04$) (Fig. 6e). Both the AAF and EHF groups displayed similar trends of total BCFA production and were significantly higher compared to HM at Day 30 ($P < 0.01$, $P = 0.015$ respectively) and Day 60 ($P < 0.01$ for both) (Fig. 6f, Additional File 1: Fig. S2). Spearman correlations were calculated to associate taxa



at the genus level with individual metabolites (Fig. S3). Notable correlations include positive correlations between acetate and *Bifidobacterium* and between butyrate and members of the Clostridia IV and XIVa clusters (*Roseburia*, *Faecalibacterium*, *Dorea*, *Coprococcus*, *Clostridium* and *[Ruminococcus]*). Butyrate was also positively correlated with *Leuconostoc*, *Pseudoramibacter_Eubacterium*, *Enterococcus*, *Eggerthella*, *Blautia*, *Akkermansia*, *[Eubacterium]* and *Citrobacter*.

Discussion

One of the most important factors affecting the development and composition of the infant gut microbiome is nutrition, specifically, the type of infant feeding [23–25]. In particular, human milk and infant formulas have been previously demonstrated to induce differences in microbiota composition [26, 27]. In the current study, two hypoallergenic infant formulas that had different sources

of protein were compared to human milk in infants from birth to Day 60. These formulas have been previously or are currently marketed, and have been demonstrated to adequately support typical growth and safety [28]. In this study, group differences in achieved growth between study formula groups and the HM reference group were detected, as could be expected. Weight gain in healthy breastfed infants has been reported as typically faster compared to those receiving formula feeding in the first few months of life, but slower over for the remainder of infancy [29].

The major groups of bacteria detected among all study groups and time points belonged to phyla known to be associated with the infant gut microbiome, including Firmicutes, Actinobacteria, Proteobacteria and Bacteroidetes [30, 31]. In particular, enrichment of *Bifidobacteriaceae* in the HM reference group was consistent with previous gut microbiome characteristics of




Fig. 6 pH and S/BCFA analysis of stool samples. For the different feeding groups; amino acid (AAF; red), extensively hydrolyzed formula (EHF; green) and human milk (HM; blue), **a** pH, **b** acetate, **c** butyrate, **d** propionate, **e** total SCFA and **f** total BCFA were measured at each visit. A repeated measure analysis of variance (ANOVA) using a Toeplitz covariance structure was used with Bonferroni's post-hoc test. Each point represents the mean and error bars represent upper and lower limits at a 95% confidence interval. * represents significant difference between visits for AAF in **a** pH and **d** propionate and EHF in **c** butyrate ($p < 0.05$). Points that do not share the same letter(s) at a given visit are significantly different from each other ($p < 0.05$)

infants receiving mother's own milk [13, 32]. In general, *Bifidobacterium* spp. typically dominate the infant gut early in life [33] especially *B. bifidum*, *B. breve* and *B. longum*, but slowly attenuate during adolescence and adulthood [34, 35]. Human milk serves as an initial source of *Bifidobacterium* [36, 37] and, importantly, also provides a continuing source of human milk oligosaccharides (HMOs) throughout lactation. HMOs are specifically metabolized by groups of bifidobacteria, *B. longum* in particular [38–41].

Abundance of bifidobacteria in the infant gut has been suggested as protective against development of allergic diseases [20, 42–46], and may be an advantage associated with breastfeeding [47]. We observed that abundance of a

B. longum ASV increased in the HM reference group but decreased in both study formula groups. In contrast, a significant increase in *B. pseudocatenulatum* was demonstrated in both study formula groups, particularly the EHF group. The presence of *B. pseudocatenulatum* has previously been observed in both breastfed infants and those receiving infant formula [48, 49], although the role of this species in the development of immune or other health parameters is unclear [48, 50].

In the current study, the trend toward higher alpha diversity was similar for infants receiving EHF or AA-based formulas, suggesting the compositional evenness and richness of taxa in the infant gut was influenced by feeding during early life. Similarly, stool microbiota

diversity has been demonstrated to be significantly higher in infants receiving formula vs human milk in US [51] and Korean populations [52]. In the US study, lower diversity in infants receiving human milk was likely due to the dominance of *Bifidobacterium*, which are enriched by HMOs [35, 38, 53]. In the current study, diversity within the HM group was stable through Days 30 and 60 (albeit an increase in Chao1 richness at Day 60), reflecting minimum change in gut community composition throughout the study period. The increase in Chao1 richness was likely influenced by an increase in the number of rare species. In contrast, the increased diversity over time for infants receiving EH or AA-based formulas was associated with enrichment of members of the phylum Firmicutes.

Whereas beta diversity measures demonstrated a lack of defined separation between groups, the overlap between the AAF and EHF groups at Day 60 further suggested greater similarity in community composition compared to the HM reference group. Nevertheless, the association between diversity and health remains undefined, partly because diversity is not reflective of ecosystem function and stability [54, 55]. Instead, the underlying ecological mechanisms driven by functionally conserved species should be considered in addition to community diversity. Although the gut microbiome is more diverse in infants receiving formula compared to human milk, the association between atopy and microbial diversity in the infant gut (as assessed across several studies) remains inconclusive [56–60]. For example, children with food sensitization in early life had lower alpha diversity compared with children without these conditions [61].

Downstream taxonomic analyses yielded similar results, suggesting that different sources of dietary protein may have been responsible for these changes in gut community composition. These changes may further be associated with the differential production of metabolites such as S/BCFA, which are known to communicate with the immune system [62].

The enrichment of Firmicutes in both study formula groups was consistent with previous reports and reflected a more adult-like microbiome [52, 63, 64]. The phylum Firmicutes includes commensal *Clostridia* species and related taxa known to produce butyrate and induce T_{reg} cells in germ-free mice [16, 65]. Indeed, a majority of the ASVs associated with butyrate production identified in the formula groups belonged to *Clostridia* IV and XIVa clusters (including *Ruminococcus*, *Dorea*, *Lachnospira*, *Eubacterium*, *Roseburia*, *Faecalibacterium* and *Coprococcus* [66, 67]), potentially accounting for the observed increase in butyrate in these groups. This is supported by the positive correlations observed between butyrate concentrations and these specific taxa. Furthermore, ASVs corresponding to *Faecalibacterium* and *Roseburia* identified in the EHF group (by both

DESeq2 differential abundance and random forest analysis) had as much as a \log_2 fold increase of 3.9. Butyrate production through cross-feeding reactions between the observed bifidobacteria and butyrate-producing organisms (similar to species demonstrated in the EHF group) has also been demonstrated previously [68, 69]. Butyrate is the main energy source for colonic epithelial cells and was shown to regulate gut permeability [70]. Butyrate producers *Roseburia* and *F. prausnitzii* are found in high numbers in the gut of healthy adults [66, 71, 72] and *F. prausnitzii* has been studied as a beneficial commensal correlated with improved health in adults [71, 73]. *Faecalibacterium* was also found to be lower in abundance in children belonging to two different birth cohorts who had higher risks in the development of atopy [74] and in children that developed allergic diseases [20]. Interestingly, enrichment of *A. muciniphila* was only observed in the AAF group with a significant fold increase from baseline to Day 60 along with higher levels of propionate throughout. *A. muciniphila* is pH sensitive, has optimum growth in environments closer to neutral pH, and produces propionate as a metabolic end product of mucin degradation [75]. Some of the described benefits of propionate include the improvement of glucose metabolism in adults [76, 77] and the prevention of allergic diseases in children [78]. An association between longer uninterrupted sleep and an increase in propionate was also observed in infants of the Baby-Led Introduction to Solids (BLISS) cohort [79].

Distinct patterns of pH and microbial metabolites were also observed for infants receiving EH or AA-based formulas compared to mother's own milk. Although higher stool pH has been previously observed in a small study of infants receiving formula vs human milk [80], a dramatic shift over the past century in mean fecal pH values among breastfed infants in developed countries (an increase from 5.0 to 6.5) was recently reported [81]. The researchers suggested that this shift was correlated with the presence and absence of specific taxa; specifically, increased pH values were associated with an increase in dysbiosis-associated taxa (*Clostridiaceae*, *Enterobacteriaceae*, *Peptostreptococcaceae* and *Veillonellaceae*) and a decrease in *Bifidobacteriaceae*. In the results presented here, the mean fecal pH of the AAF group at Days 30 and 60 was more than 1 pH unit higher than the range reported in Henrick et al. [81] and significantly higher compared to the EHF and HM reference groups. Similar taxonomic shifts were also observed, including a significant increase in *Clostridiaceae* and *Enterobacteriaceae* and decrease in *Bifidobacteriaceae* in the AAF group compared to the HM group. The role of these species in amino acid fermentation and metabolism can potentially influence the observed differences in pH [82, 83]. Additionally, increased BCFA in the AAF and EHF groups

was consistent with free branched-chain amino acid fermentation in the colon [84, 85].

Although butyrate was higher for both study groups compared to HM at Day 60, a significant increase from baseline to Day 60 was evident only for the EHF group. This finding, along with the presence of butyrate-producing organisms in the EHF group, may provide insights into the T_{reg} -associated mechanisms by which an EH formula more effectively accelerates oral tolerance acquisition in children with CMA versus an AA-based formula [4, 20, 86]. Previously, the role of FOXP3⁺ T_{reg} cells and its mechanisms in the development of oral tolerance have been described [86]. Other studies have demonstrated the presence of higher frequencies of circulating T_{reg} cells in children who acquired spontaneous tolerance [18] and in children who outgrew CMA [87]. Importantly, butyrate has been linked to T_{reg} stimulation by increasing acetylation of FOXP3 and improving accessibility of transcriptional regulators at the gene promoter region and other enhancer elements [16]. The association between butyrate-producing bacteria and T_{reg} cell maturation was also evident after the first year of life in a birth-cohort of Estonian and Finnish children [20]. In that study, highly activated T_{reg} cells increased and demonstrated a strong association with the butyrate-producing bacteria, thus increasing diversity of the intestinal microbiome. Furthermore, shotgun metagenomic sequencing of infant stool samples from the Canadian Healthy Infant Longitudinal Development (CHILD) cohort demonstrated that infants who developed allergic sensitization later on in life were deficient in butyrate-producing genes since 3 months of age [58].

Early diet choices may influence childhood development during the first 1000 days of life and beyond. Together with previous reports, our study suggests that using an EH formula may accelerate oral tolerance acquisition by supporting a microbiome that is capable of producing butyrate. The EH formula was associated with lower pH, shifted the microbiota composition toward butyrate production (e.g., *Roseburia*, *F. prausnitzii*), and altered the SCFA profile (more butyrate vs propionate and acetate) compared to an AA-based formula. Further research is warranted in this area.

Conclusions

The gut microbiome plays a critical role in the regulation of allergic immune responses. Several distinct patterns of early neonatal microbiome, pH, and microbial metabolites were demonstrated for infants receiving mother's own milk compared to amino acid-based or extensively hydrolyzed protein formulas. The abundance of *Bifidobacterium* was higher in breastfed infants, and Firmicutes were dominant in both of the infant formula groups. Shifts in specific bacteria species were associated

with production of metabolites, particularly butyrate, that is known to communicate with the host immune system. Within the group receiving an EH formula, specific taxonomic shifts included the enrichment of butyrate producers, potentially linked to the induction of oral tolerance to cow milk proteins. However, it is not clear if these outcomes are mediated through changes in the microbiome.

Results from this study suggest that formulas with different protein sources affect the microbiome differently, possibly impacting development and functionality of the immune response. Longitudinal studies that include both microbiome measurements and observations of immunological effects are needed to fully understand the mechanisms by which these infant formulas function. In addition, use of whole shotgun metagenomic sequencing to uncover species and microbial pathways that contribute towards the production of beneficial metabolites is needed. Finally, although these findings using stool samples provide a basis for understanding the influence of particular types of formula feeding on the infant colonic microbiota, just as for other studies based on fecal samples, they may not fully reflect the conditions along the entire intestinal tract.

Methods

Study population

Healthy, term infants (1 to 7 days of age) were recruited at four clinical sites in the United States. Eligible infants were singleton births at 37–42 weeks gestational age (GA) with appropriate birth weight for GA (defined as birth weight between and inclusive of 5th and 95th percentiles [88, 89]; and started either infant formula feeding or mother's own breast milk feeding within 24 h of birth. Infants whose mothers had chosen not to breastfeed were solely formula-fed at least 24 h prior to randomization. Infants from mother who intended to breastfeed exclusively received mother's-own breast milk from Day 1 (day of birth was considered Day 0) through study registration. Exclusion criteria included: caesarean delivery; birth mother who had Type 1 diabetes; history of underlying disease or congenital malformation likely to interfere with normal growth and development or participant evaluation; evidence of feeding difficulties (from breast or bottle) or history of formula intolerance; and immunodeficiency; signs of acute infection or use of antibiotics (including topical antibiotics in the diaper area) at study randomization/registration; and planned use of probiotics during the study period.

Study design

This study was designed to examine the impact of early feeding of EH casein formula on intestinal microbiota

composition. At the time of study inception, little data existed on which to base a formal sample size calculation. However, microbiota differences had been demonstrated in a study with two groups of 18 infants each [50]. Therefore, 20 infants per group were targeted to complete the study feeding period. In this double-blind, randomized, controlled, parallel-designed, prospective trial participants were enrolled between August 2015 and May 2017. Parents or legally authorized representative(s) provided written informed consent prior to enrollment. The research protocol and informed consent forms observing the Declaration of Helsinki were approved by Schulman IRB. Participants receiving infant formula were randomly assigned to receive one of two study formulas (Mead Johnson Nutrition, Evansville, IN): an amino acid-based infant formula (AAF; marketed PurAmino) or an extensively hydrolyzed protein infant formula (EHF; previously marketed Nutramigen®) through 60 days of age. Neither study formula included added *Lactobacillus rhamnosus* GG. Similarly to Yeiser et al. ([90]), a computer-generated randomization schedule was prepared and inserted into sealed envelopes that were consecutively-numbered. The individual study formulas were designated using one of two unique codes. Study formulas assigned to each participant were determined after opening the next sequential envelope. The codes were known only to the sponsor. Formulas were provided directly to parents at each visit prior to completion of the study or to withdrawal.

Neither the sealed envelopes nor the product labels permitted unblinding by the study site. In addition, the personnel involved in monitoring the study were blinded to product identification. Only in the event of a medical emergency that required knowledge of the study formula for managing the participant's management, could blinding be broken. In this study, there were no instances where it was necessary to prematurely break the study code.

Participants exclusively receiving mother's own breast milk were registered and assigned to a human milk (HM) reference group. Study visits occurred at Baseline (1–7 days of age), 30 (± 3) days and 60 (± 3) days of age. Anthropometric measures (body weight, length, and head circumference) were recorded at all study visits. Parents collected Baseline stool samples after meconium passed and ≤ 24 h of participant study enrollment. Day 30 and 60 stool samples were collected ± 24 h of the study visit and compliant samples were stored onsite at -20 °C. Study completion was defined as participants who provided a protocol-compliant stool sample at all three study time points. (Stool sample compliance criteria: Additional File 1, Table S2). Serious adverse events were collected throughout the study.

pH and S/BCFA analysis

A standard pH meter (Orion Research Inc., Boston, Mass., USA) with a micro combination electrode (Fisher Scientific, Lenexa, Kansas) was used to measure pH of diluted (1:10, deionized water) and homogenized stool samples. Short chain fatty acids (SCFA; acetate, butyrate and propionate) and branched chain fatty acids (BCFA; isovalerate and isobutyrate) were measured using gas chromatography as described previously [91] with slight modifications. Briefly, diluted, homogenized stool samples (1:10; phosphate-buffered saline) were centrifuged ($8000 \times g \times 5$ min); pellets were stored at -20 °C (for subsequent DNA extraction). Supernatant was collected (0.4 ml), and diethyl ether extracts were prepared and quantified by gas chromatography (Clarus 580; PerkinElmer, Waltham, MA, USA) using a fused silica capillary column (Nukol 30 m \times 0.25 mm id \times 0.25 μ m film; Sigma-Aldrich, St. Louis, MO, USA) and a flame ionization detector. Quantification of S/BCFA was based on calculating response factors relative to known concentrations of 2-ethyl butyric acid. Internal standards of 2-ethyl butyric were used during quantification to correct for any variability caused by loss of analyte.

DNA extraction, 16S rRNA community sequencing and analysis

DNA from stool samples were extracted using phenol-chloroform as described by [92] with the exception that all incubation times were carried out for 30 min and DNA was recovered with 100 μ l of DNase-free water. Amplicon sequencing was performed by Neogen GeneSeek Operations (Lincoln, NE). Briefly, 2x250bp paired-end 16S rRNA regions of the DNA samples were sequenced with an Illumina MiSeq sequencer. Primers used were 515F (5'-GTGCCAGCMGCCGCGGTAA-3') and 806R (5'-GGACTACHVGGGTWTCTAAT-3'), flanking the 515 and 806 region. Barcodes were attached to the 806R primers. A total of 8,789,037 sequences were obtained with a mean of 51,099 sequences per sample.

Sequence analysis was conducted using QIIME 2.0: Quantitative Insights Into Microbial Ecology [93]. Paired-end raw sequences were de-multiplexed and imported into QIIME. FastQC was used to check for per sample sequence quality and DADA2 was used to remove chimeric sequences [94]. To retain high quality sequences, forward reads were truncated to 240 bp and reverse reads were truncated to 200 bp. In total, 6,043, 211 sequences were de-replicated into unique amplicon sequence variants (ASV) and a list of representative sequences with 619 features was created. Taxonomy was successfully assigned to 557 features using the Greengenes database with a pre-trained classifier based on 99% sequence identity. In the Greengenes database,

square brackets around taxonomy indicate suggested but not verified taxonomy by the database curators. Alpha and beta diversity measures were computed using a sample depth of 9351 sequences. Species-level taxonomic information that could not be obtained from the Greengenes database was further identified through BLASTn against the NCBI Refseq database and the top hits were used as an identifier.

Statistical analysis

Analyses on measured pH and S/BCFA were performed using Statistical Analytical System (SAS) software ver. 9.4 (SAS Inst., Cary, NC, USA). Differences in pH and S/BCFA production between each group-visit combination were analysed with a repeated measure analysis of variance (ANOVA) using a Toeplitz covariance structure. The differences between the least square means of fixed effects were used to compare between group-visit combinations. To account for multiple comparisons, a Bonferroni adjustment was used and $p < 0.05$ was considered significant. In this model, 'group' and 'visit' were the fixed effects while 'visit' was the repeated measure and subject within group was used as the random error. Data transformations were used to adjust for normality; double square root transformation for acetate, butyrate and total SCFAs and cubic transformation for propionate and isovalerate. To adjust for the inflated number of zeros observed (not detectable) in the measurement of isobutyrate throughout the samples, an analysis of probability of a zero observation was carried out. Then, a modified log transformation was used to adjust for normality after the removal of zeros from the dataset.

Statistical analysis for 16S rRNA community sequencing was done in QIIME2 and R (ver 3.6.1). Shannon, Simpson, and Chao1 richness indices were computed at the ASV level to measure alpha diversity. For every group-visit combination, pairwise comparisons of interests (between visits in all three feeding groups and between groups at visits 1 and 3) were made using Kruskal-Wallis tests. FDR correction was incorporated for all statistical test and significance was determined with a significance cutoff at 0.05. For beta diversity, the vegan R package was used to compute Bray Curtis dissimilarity matrix which was further analyzed with a permutational multivariate analysis of variance (PERMANOVA) test. Principal Coordinates Analysis (PCoA) plots were drawn based on Bray Curtis distance matrix. Comparisons of community composition were conducted at the ASV level.

To identify significant differences in taxonomic composition between visits or feeding groups, features with very low counts and those that are unlikely to be significant in comparison analyses were filtered out and excluded. This includes removal of features that were

singletons and were only detected in a single sample. Additionally, features with variances that were among the lowest 10% were also removed to improve accuracy of comparative analyses. After subsequent filtering, 249 features which were composed of 72 genera, were used for subsequent analyses. Raw values of relative abundances are located in Additional File 2: Table S3. To assess taxonomic differences between groups and/or visits, multiple approaches were used. Analyses in R included Wilcoxon tests of taxonomic abundance, DESeq2 [95] and random forest classification.

Log₂-fold change of median proportions were calculated, and significant testing was carried out. Pairwise Wilcoxon signed rank test with FDR correction was used to identify significantly different genera between visits for each feeding group and pairwise Wilcoxon rank sum test with FDR correction was used to compare genera between feeding groups at day 60. Metacoder [96] was used to generate heatmap trees. For visualization purposes, features that appeared in less than three samples or had fewer than 10 reads per sample and were not statistically significant were excluded from the heat trees (although still considered during significance testing). A reference tree was generated for the heatmap trees.

The random Forest package in R was used to carry out a random forest classification analysis to identify top predictors (genera) that discriminate between baseline and day 60 for each feeding group. DESeq2 was used to compare and identify specific ASVs that were significantly different between baseline and day 60 for each feeding group. ASVs with an FDR < 0.05 were considered significant. Shrinkage estimations of log₂ fold change values were computed. A high positive fold-change does not necessarily reflect high abundance and should be interpreted as an increase in a specific ASV from baseline to Day 60.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12866-020-01991-5>.

Additional file 1: Table S1. Demographics of study participants. **Table S2.** Study protocol stool sample compliance criteria at Baseline, Day 30, and Day 60. **Figure S1.** Variable importance plots from random forest analysis using mean decrease in accuracy. **Figure S2.** Individual branched chain fatty acids; **a** isobutyrate and **b** isovalerate measured for the different feeding groups; amino acid (AAF; red), extensively hydrolyzed formula (EHF; green) and human milk (HM; blue). **Figure S3.** Spearman correlations of SCFA concentration with bacterial taxa. + indicates significant correlation and metabolite concentration (FDR < 0.05).

Additional file 2: Table S3. Relative abundances of amplicon sequence variants present in infant fecal samples throughout all treatment and timepoints. **Table S4.** Relative abundances of amplicon sequence variants present in individual infant fecal samples. Each column represents an individual fecal sample within a particular treatment and timepoint.

Abbreviations

EHF: Extensively hydrolyzed formula; AAF: Amino acid formula; HM: Human milk; 16S rRNA: 16S ribosomal RNA; SCFA: Short chain fatty acids; BCFA: Branched chain fatty acids; ANOVA: Analysis of variance; CMA: Cow's milk allergy; T_{reg} cells: Regulatory T cells; PCoA: Principal coordinate analysis; PERMANOVA: Permutational multivariate analysis of variance; ASV: Amplicon sequence variant; HMO: Human milk oligosaccharides; CHILd: Canadian healthy infant longitudinal development; GA: Gestational age

Acknowledgements

We thank parents and infants for participating in this study. We also thank study site staff for cooperation on this project and the Statistical Cross-disciplinary Collaboration and Consulting Lab (SC3L) at the University of Nebraska-Lincoln for statistical assistance.

Authors' contributions

JAV conceptualized and designed the study. BB supervised data collection. RH directed the microbiome analytical plan. CLH participated in study design and performed statistical analyses. MC and JLW participated in study design. NM participated in study design and study coordination. CK performed laboratory analyses, all bioinformatics analyses, and drafted the initial manuscript. DR assisted with laboratory analyses. All authors interpreted data, contributed to the intellectual content, and critically reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work

Funding

This study was funded by Mead Johnson Nutrition (Evansville, IN, USA). The Midwest Children's Health Research Institute, LLC (Lincoln, NE, USA) was provided funding for study site management. The Department of Food Science and Technology, University of Nebraska-Lincoln (Lincoln, NE, USA) was provided funding for stool sample analysis, bioinformatics, and student travel to support conference abstract presentations.

Availability of data and materials

The raw 16S rRNA sequences are deposited in the NCBI database under BioProject ID PRJNA612727 (<https://www.ncbi.nlm.nih.gov/bioproject/612727>).

Ethics approval and consent to participate

Written informed consent was obtained from parents or legally authorized representative(s) prior to enrollment in the study. The informed consent forms and research protocol observing the Declaration of Helsinki (including October 1996 amendment) were approved by the Schulman Institutional Review Board (now known as Advarra, Columbia, MD), with reference number MJN 6032. The study complied with good clinical practices.

Consent for publication

Not applicable.

Competing interests

CK was funded by a grant from Mead Johnson Nutrition. RH is a member of the Board of Directors of the International Scientific Association for Probiotics and Prebiotics, has received funding and honoraria from industry sources involved in the manufacture and marketing of probiotics and prebiotics, and is a co-owner of Synbiotics Health. MC, CLH, NM, JLW, and JAV are employed by the study sponsor, Mead Johnson Nutrition.

Author details

¹Department of Food Science and Technology, University of Nebraska-Lincoln, Lincoln, NE 68588, USA. ²Midwest Children's Health Research Institute, LLC, 3262 Salt Creek Circle, Lincoln, NE 68504, USA. ³Global Nutrition Science, Mead Johnson Nutrition, Evansville, IN 47721, USA. ⁴Clinical Research, Department of Medical Affairs, Mead Johnson Nutrition, Evansville, IN 47721, USA. ⁵Boston Children's Hospital, Gastroenterology, 300 Longwood Avenue, Boston, MA 02115, USA. ⁶Department of Food Science and Technology, University of Nebraska, 268 Food Innovation Center, Lincoln, NE 68588-6205, USA. ⁷Department of Food Science and Technology, University of Nebraska, 258 Food Innovation Center, Lincoln, NE 68588-6205, USA.

Received: 9 June 2020 Accepted: 30 September 2020

Published online: 09 November 2020

References

- Sicherer SH. Epidemiology of food allergy. *J Allergy Clin Immunol*. 2011;127:594–602.
- Koletzko AS, Niggemann B, Arato A, Dias JA, Heuschkel R, Husby S, et al. Diagnostic approach and management of cow's-milk protein allergy in infants and children: ESPGHAN GI committee practical guidelines. *J Pediatr Gastroenterol Nutr*. 2012;55:221–9.
- de Boissieu D, Matarazzo P, Dupont C. Allergy to extensively hydrolyzed cow milk proteins in infants: identification and treatment with an amino acid-based formula. *J Pediatr*. 1997;131:744–7.
- Canani RB, Nocerino R, Terrin G, Frediani T, Lucarelli S, Cosenza L, et al. Formula selection for management of children with cow's milk allergy influences the rate of acquisition of tolerance: a prospective multicenter study. *J Pediatr*. 2013;163:771–7.
- Katz Y, Rajuan N, Goldberg MR, Eisenberg E, Heyman E, Cohen A, et al. Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy. *J Allergy Clin Immunol*. 2010;128:77–82.
- Snijders BEP, Thijs C, van Ree R, van Den Brandt PA. Age at first introduction of cow milk products and other food products in relation to infant atopic manifestations in the first 2 years of life: the KOALA birth cohort study. *Pediatrics*. 2008;122:e115–22.
- Kiewiet MBG, Gros M, van Neerven RJJ, Faas MM, de Vos P. Immunomodulating properties of protein hydrolysates for application in cow's milk allergy. *Pediatr Allergy Immunol*. 2015;26:206–17.
- von Berg A. The role of hydrolysates for allergy prevention - pro. *Pediatr Allergy Immunol*. 2013;24:720–3.
- Stefka AT, Feehley T, Tripathi P, Qiu J, Mccoy K, Mazmanian SK, et al. Commensal bacteria protect against food allergen sensitization. *PNAS*. 2014;111:13145–50.
- Canani RB, Gilbert JA, Nagler CR. The role of the commensal microbiota in the regulation of tolerance to dietary allergens. *Curr Opin Allergy Clin Immunol*. 2015;15:243–9.
- Arpaia N, Campbell C, Fan X, Dikiy S, Van Der Veecken J, Deroos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature*. 2013;504:451–6.
- Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. *J Allergy Clin Immunol*. 1997;99:179–85.
- Canani RB, Sangwan N, Stefka AT, Nocerino R, Paparo L, Aitoro R, et al. *Lactobacillus rhamnosus* GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants. *ISME J*. 2016;10:742–50.
- Tan J, McKenzie C, Vuillermin PJ, Goverse G, Vinuesa CG, Mebius RE, et al. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. *Cell Rep*. 2016;15:2809–24.
- Fujimura KE, Lynch SV. Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. *Cell Host Microbe*. 2015;17:592–602.
- Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature*. 2013;504:446–50.
- Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? *Trends Microbiol*. 2004;12:562–8.
- Perezabad L, López-Abente J, Alonso-Lebrero E, Seoane E, Pion M, Correa-Rocha R. The establishment of cow's milk protein allergy in infants is related with a deficit of regulatory T cells (T_{reg}) and vitamin D. *Pediatr Res*. 2017;81:722–30.
- Shreffler WG, Wanich N, Moloney M, Nowak-Wegrzyn A, Sampson HA, York N. Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein. *J Allergy Clin Immunol*. 2009;123.
- Ruotula T, de Goffau MC, Nieminen JK, Honkanen J, Siljander H, Hämäläinen A-M, et al. Maturation of gut microbiota and circulating regulatory T cells and development of IgE sensitization in early life. *Front Immunol*. 2019;10:2494.
- Kok C, Brabec B, Chichlowski M, Harris C, Moore N, Wampler J, et al. Stool microbiota in infants receiving extensively hydrolyzed formula, amino acid formula, or human milk through two months of age (FS04-07-19). *Curr Dev Nutr*. 2019;3(Supplement_1).
- Kok C, Brabec B, Chichlowski M, Harris C, Moore N, Wampler J, et al. Stool pH and short/branched chain fatty acids in infants receiving extensively

- hydrolyzed formula, amino acid formula, or human milk through two months of age (P11–076–19). *Curr Dev Nutr.* 2019;3(Supplement_1).
23. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe.* 2015;17:690–703.
 24. Gritz EC, Bhandari V. The human neonatal gut microbiome: a brief review. *Front Pediatr.* 2015;3:17.
 25. Marques TM, Wall R, Ross RP, Fitzgerald GF, Ryan CA, Stanton C. Programming infant gut microbiota: influence of dietary and environmental factors. *Curr Opin Biotechnol.* 2010;21:149–56.
 26. Gomez-Llorente C, Plaza-Diaz J, Aguilera M, Muñoz-Quezada S, Bermudez-Brito M, Peso-Echarri P, et al. Three main factors define changes in fecal microbiota associated with feeding modality in infants. *J Pediatr Gastroenterol Nutr.* 2013;57:461–6.
 27. Martin R, Makino H, Cetinyurek Yavuz A, Ben-Amor K, Roelofs M, Ishikawa E, et al. Early-life events, including mode of delivery and type of feeding, siblings and gender, shape the developing gut microbiota. *PLoS One.* 2016;11:e0158498.
 28. Burks W, Jones SM, Berseth CL, Harris C, Sampson HA, Scalabrini DMF. Hypoallergenicity and effects on growth and tolerance of a new amino acid-based formula with docosahexaenoic acid and arachidonic acid. *J Pediatr.* 2008;153:266–71.
 29. Grummer-Strawn LM, Reinold C, Krebs NF. Use of world health organization and CDC growth charts for children aged 0–59 months in the United States. *Morb Mortal Wkly Rep.* 2010;59:RR-9.
 30. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. *PLoS Biol.* 2007;5:e177.
 31. D'Argenio V, Salvatore F. The role of the gut microbiome in the healthy adult status. *Clin Chim Acta.* 2015;451:97–102.
 32. Tannock GW, Lawley B, Munro K, Gowri Pathmanathan S, Makrides M, Gibson RA, et al. Composition of the stool microbiotas of infants fed goat milk-formula in comparison to cow milk-based formula, or breast milk. *Appl Environ Microbiol.* 2013;79:3040–8.
 33. Cukrowska B, Biera JB, Zakrzewska M, Klukowski M, Maciorkowska E. The relationship between the infant gut microbiota and allergy. The role of *Bifidobacterium breve* and prebiotic oligosaccharides in the activation of anti-allergic mechanisms in early life. *Nutrients.* 2020;12:946.
 34. Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Doré J, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. *BMC Microbiol.* 2009;9:123.
 35. Turrioni F, Milani C, Duranti S, Ferrario C, Lugli GA, Mancabelli L, et al. Bifidobacteria and the infant gut: an example of co-evolution and natural selection. *Cell Mol Life Sci.* 2018;75:103–18.
 36. Peirotn A, Arqués JL, Medina M, Rodríguez-Minguez E. Bifidobacterial strains shared by mother and child as source of probiotics. *Benef Microbes.* 2018;9:231–8.
 37. Qian L, Song H, Cai W. Determination of *Bifidobacterium* and *Lactobacillus* in breast milk of healthy women by digital PCR. *Benef Microbes.* 2016;7:559–69.
 38. Sela DA, Mills DA. Nursing our microbiota: beneficial linkages between bifidobacteria and milk oligosaccharides. *Trends Microbiol.* 2010;18:298–307.
 39. Andreas NJ, Kampmann B, Le-Doare M. Human breast milk: a review on its composition and bioactivity. *Early Hum Dev.* 2015;91:629–35.
 40. Grönlund M, Gueimonde M, Laitinen K, Kociubinski G, Gronroos T, Salminen S, et al. Maternal breast-milk and intestinal bifidobacteria guide the compositional development of the *Bifidobacterium* microbiota in infants at risk of allergic disease. *Pediatr Res.* 2012;52:57–63.
 41. Matamoros S, Gras-Leguen C, Le Vacon F, Potel G, de La Cochetiere M-F. Development of intestinal microbiota in infants and its impact on health. *Trends Microbiol.* 2013;21:167–73.
 42. Fieten KB, Totté JEE, Levin E, Reyman M, Meijer Y, Knulst A, et al. Fecal microbiome and food allergy in pediatric atopic dermatitis: a cross-sectional pilot study. *Int Arch Allergy Immunol.* 2018;175:77–84.
 43. Sjögren YM, Jenmalm MC, Böttcher MF, Björkstén B, Sverremark-Ekström E. Altered early infant gut microbiota in children developing allergy up to 5 years of age. *Clin Exp Allergy.* 2009;39:518–26.
 44. Kalliomäki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. *J Allergy Clin Immunol.* 2001;107:129–34.
 45. Björkstén B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. *Clin Exp Allergy.* 1999;29:342–6.
 46. Low JSY, Soh S-E, Lee YK, Kwek KYC, Holbrook JD, Van der Beek EM, et al. Ratio of *Klebsiella/Bifidobacterium* in early life correlates with later development of paediatric allergy. *Benef Microbes.* 2017;8:681–95.
 47. Victora CG, Bahl R, Barros AJD, França GVA, Horton S, Krasevec J, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. *Lancet.* 2016;387:475–90.
 48. Gore C, Munro K, Lay C, Ro B, Morris J, Woodcock A, et al. *Bifidobacterium pseudocatenulatum* is associated with atopic eczema: a nested case-control study investigating the fecal microbiota of infants. *J Allergy Clin Immunol.* 2008;121:135–40.
 49. Lawson MAE, O'Neill UJ, Kujawska M, Gowrinadh Javvadi S, Wijeyesekera A, Flegg Z, et al. Breast milk-derived human milk oligosaccharides promote *Bifidobacterium* interactions within a single ecosystem. *ISME J.* 2020;14:635–48.
 50. de Goffau MC, Luopajarvi K, Knip M, Ilonen J, Ruotula T, Härkönen T, et al. Fecal microbiota composition differs between children with β -cell autoimmunity and those without. *Diabetes.* 2013;62:1238–44.
 51. Yatsunenok T, Rey FE, Manary MJ, Trehan J, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. *Nature.* 2012;486:222–7.
 52. Lee SA, Ye Lim J, Kim B-S, Jin Cho S, Yon Kim N, Bin Kim O, et al. Comparison of the gut microbiota profile in breast-fed and formula-fed Korean infants using pyrosequencing. *Nutr Res Pract.* 2015;9:242–8.
 53. Bezirtzoglou E, Tsiotsias A, Welling GW. Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH). *Anaerobe.* 2011;17:478–82.
 54. Shade A. Diversity is the question, not the answer. *ISME J.* 2017;11:1–6.
 55. Duar RM, Henrick BM, Casaburi G, Frese SA. Integrating the ecosystem services framework to define dysbiosis of the breastfed infant gut: the role of *B. infantis* and human milk oligosaccharides. *Front Nutr.* 2020;7:33.
 56. Lee MJ, Kang MJ, Lee SY, Lee E, Kim K, Won S, et al. Perturbations of gut microbiome genes in infants with atopic dermatitis according to feeding type. *J Allergy Clin Immunol.* 2018;141:1310–9.
 57. Nylund L, Nermes M, Isolauri E, Salminen S, de Vos WM, Satokari R. Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate-producing bacteria. *Allergy.* 2015;70:241–4.
 58. Cait A, Cardenas E, Dimitriu PA, Amenyogbe N, Dai D, Cait J, et al. Reduced genetic potential for butyrate fermentation in the gut microbiome of infants who develop allergic sensitization. *J Allergy Clin Immunol.* 2019;144:1638–47.
 59. Arrieta M-C, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci Transl Med.* 2015;7:307ra152.
 60. Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC. Low diversity of the gut microbiota in infants with atopic eczema. *J Allergy Clin Immunol.* 2012;129:434–40.
 61. Chen C-C, Chen K-J, Kong M-S, Chang H-J, Huang J-L. Alterations in the gut microbiotas of children with food sensitization in early life. *Pediatr Allergy Immunol.* 2016;27:254–62.
 62. Kim CH. Immune regulation by microbiome metabolites. *Immunology.* 2018;154:220–9.
 63. Wang M, Li M, Wu S, Lebrilla CB, Chapkin RS, Ivanov I, et al. Fecal microbiota composition of breast-fed infants is correlated with human milk oligosaccharides consumed. *J Pediatr Gastroenterol Nutr.* 2015;60:825–33.
 64. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. *Nature.* 2011;473:175–80.
 65. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. T_{reg} induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature.* 2013;500:232–8.
 66. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. *FEMS Microbiol Lett.* 2002;217:133–9.
 67. Lopetuso LR, Scaldaferrri F, Petito V, Gasbarrini A. Commensal Clostridia: leading players in the maintenance of gut homeostasis. *Gut Pathog.* 2013;5:23.
 68. Rios-Covian D, Gueimonde M, Duncan SH, Flint HJ, De Los Reyes-Gavilan CG. Enhanced butyrate formation by cross-feeding between *Faecalibacterium prausnitzii* and *Bifidobacterium adolescentis*. *FEMS Microbiol Lett.* 2015;362:fnv176.
 69. Falony G, Vlachou A, Verbrugghe K, De Vuyst L. Cross-feeding between *Bifidobacterium longum* BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose. *Appl Environ Microbiol.* 2006;72:7835–41.
 70. Peng L, Li Z-R, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. *J Nutr.* 2009;139:1625.

71. Miquel S, Martín R, Bridonneau C, Robert V, Sokol H, Bermúdez-Humarán LG, et al. Ecology and metabolism of the beneficial intestinal commensal bacterium *Faecalibacterium prausnitzii*. *Gut Microbes*. 2014;5:146–51.
72. Jost T, Lacroix C, Braegger CP, Chassard C. New insights in gut microbiota establishment in healthy breast fed neonates. *PLoS One*. 2012;7:44595.
73. Martín R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, et al. Functional characterization of novel *Faecalibacterium prausnitzii* strains isolated from healthy volunteers: A step forward in the use of *F prausnitzii* as a next-generation probiotic. *Front Microbiol*. 2017;8:1226.
74. Fujimura KE, Sitarik AR, Havstad S, Lin DL, Levan S, Fadrosch D, et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. *Nat Med*. 2016;22:1187–91.
75. Van Herreweghen F, Van den Abbeele P, De Mulder T, De Weirdt R, Geirnaert A, Hernandez-Sanabria E, et al. In vitro colonisation of the distal colon by *Akkermansia muciniphila* is largely mucin and pH dependent. *Benef Microbes*. 2017;8:81–96.
76. Chambers ES, Byrne CS, Morrison DJ, Murphy KG, Preston T, Tedford C, et al. Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. *Gut*. 2019;68:1430–8.
77. Chambers ES, Viardot A, Psychas A, Morrison DJ, Murphy KG, Zac-Varghese SEK, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. *Gut*. 2015;64:1744–54.
78. Roduit C, Frei R, Ferstl R, Loeliger S, Westermann P, Rhyner C, et al. High levels of butyrate and propionate in early life are associated with protection against atopy. *Allergy*. 2019;74:799–809.
79. Heath A-LM, Haszard JJ, Galland BC, Blair L, Rehrer NJ, Drummond LN, et al. Association between the faecal short-chain fatty acid propionate and infant sleep. *Eur J Clin Nutr*. 2020.
80. Kumiko O, Ben RA, Pons S, de Paolo MIL, Fernandez LB. Volatile fatty acids, lactic acid, and pH in the stools of breast-fed and bottle-fed infants. *J Pediatr Gastroenterol Nutr*. 1992;15:248–52.
81. Henrick BM, Hutton AA, Palumbo MC, Casaburi G, Mitchell RD, Underwood MA, et al. Elevated fecal pH indicates a profound change in the breastfed infant gut microbiome due to reduction of *Bifidobacterium* over the past century. *mSphere*. 2018;3:e00041–18.
82. Dai ZL, Wu G, Zhu WY. Amino acid metabolism in intestinal bacteria: links between gut ecology and host health. *Front Biosci*. 2011;16:1768–86.
83. Diether NE, Willing BP. Microbial fermentation of dietary protein: an important factor in diet–microbe–host interaction. *Microorganisms*. 2019;7:19.
84. Neis E, Dejong C, Rensen S, Neis EPJG, Dejong CHC, Rensen SS. The role of microbial amino acid metabolism in host metabolism. *Nutrients*. 2015;7:2930–46.
85. Macfarlane GT, Gibson GR, Beatty E, Cummings JH. Estimation of short-chain fatty acid production from protein by human intestinal bacteria based on branched-chain fatty acid measurements. *FEMS Microbiol Ecol*. 1992;101:81–8.
86. Rivas MN, Chatila TA. Regulatory T cells in allergic diseases. *J Allergy Clin Immunol*. 2016;138:639–52.
87. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. *J Exp Med*. 2004;199:1679–88.
88. WHO Multicentre Growth Reference Study Group. WHO child growth standards based on length/height, weight and age. *Acta Paediatr Suppl*. 2006;450:76–85.
89. WHO: WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Heal Organ; 2006.
90. Yeiser M, Harris CL, Kirchoff AL, Patterson AC, Wampler JL, Zissman EN, et al. Growth and tolerance of infants fed formula with a new algal source of docosahexaenoic acid: double-blind, randomized, controlled trial. *Prostaglandins Leukot Essent Fat Acids*. 2016;115:89–96.
91. Yang J, Rose DJ. Long-term dietary pattern of fecal donor correlates with butyrate production and markers of protein fermentation during in vitro fecal fermentation. *Nutr Res*. 2014;34:749–59.
92. Martínez I, Stegen JC, Maldonado-Gómez MX, Eren AM, Siba PM, Greenhill AR, et al. The gut microbiota of rural Papua new Guineans: composition, diversity patterns, and ecological processes. *Cell Rep*. 2015;11:527–38.
93. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol*. 2019;37:862–7.
94. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: high-resolution sample inference from illumina amplicon data. *Nat Methods*. 2016;13:581–3.
95. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15:550.
96. Foster ZSL, Sharpton TJ, Grünwald NJ, Lefort M, Malumbres-Olarte J, Vink C. Metacoder: an R package for visualization and manipulation of community taxonomic diversity data. *PLoS Comput Biol*. 2017;13:e1005404.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

